Enzymatic DNA Synthesis Market Size, Share and Trends Analysis, By Product and Services (Instruments & Platforms, Reagents & Consumables, Software & Bioinformatics, and Services), By Technology, By Synthesis Length (Short Oligonucleotide, Medium-Length, and Long DNA Contructs), By Application, By End-Use, and By Region, Forecast 2026-2033

Enzymatic DNA Synthesis Market Overview and Key Insights:

Enzymatic DNA synthesis (EDS) market size reached USD 322.3 Million in 2025 and is expected to register a revenue CAGR of 28.4% during the forecast period. EDS is a potent alternative that uses biological catalysts in aqueous conditions to produce the complex nucleic acids needed for next-generation medicines. In recent years, researchers’ need for synthetic nucleic acids have grown considerably in size and complexity. This approach, which mimics the natural enzymatic processes used by live organisms to construct DNA, has various advantages over chemical synthesis, including the ability to produce longer, more complex sequences with greater accuracy and fewer errors.

Market Drivers:

Rising demand for synthetic biology is a key driver driving the market revenue growth. Enzymatic DNA synthesis relies on specialized DNA polymerases that do not require a template strand for DNA synthesis. These polymerases may add nucleotides to a developing DNA strand in a regulated manner, either by sequence-specific signals or at random, depending on the application. Chemical DNA synthesis yield and fidelity decrease as sequence length grows. Accurately synthesizing DNA sequences longer than ~200 nucleotides are problematic due to the accumulation of errors with each addition. In contrast, enzymatic synthesis mirrors the natural methods by which cells manufacture DNA. These techniques can produce extremely long DNA sequences, such as complete genomes, with far lower error rates.

As a result, enzymatic approaches may be able to synthesize DNA sequences that are dozens or even millions of base pairs long, far exceeding the restrictions of chemical synthesis. Enzymatic synthesis is often performed in milder circumstances, with aqueous solutions at physiological pH. This decreases environmental effect and may allow for synthesis in more delicate systems, such as within living cells. The reduced requirement for purification and chemical handling also helps to minimize overall costs, making it an attractive method for large-scale applications such as synthetic biology and industrial DNA manufacturing.

On January 2026, Integrated DNA Technologies (IDT), a Danaher subsidiary and a global genomics leader, and Ansa Biotechnologies, Inc., a trusted DNA synthesis partner, have announced a strategic partnership that will add new complementary capabilities to IDT’s synthetic biology portfolio. IDT will collaborate with Ansa’s cutting-edge enzymatic DNA synthesis platform to accelerate the delivery of demanding motifs, higher complexity, and longer structures.

Market Opportunity:

Decentralized DNA manufacturing act as opportunity for enzymatic DNA synthesis market. Enzymatic DNA synthesis allows for precise and complicated DNA sequence creation, making it a key tool for developing compact protein circuits. Its influence spans a wide range of sectors, including time-sensitive medical therapies, industrial biotechnology, and environmental sustainability. Enzymatic DNA synthesis has enabled the manufacture of high-value biomolecules like enzymes, antibodies, and biopharmaceuticals. These circuits optimize manufacturing processes, resulting in higher yields and cheaper costs by precisely controlling metabolic pathways.

These advances are not confined to large-scale commercial applications; enzymatic DNA synthesis has also enabled small-scale, decentralized production systems, such as portable biomanufacturing platforms in remote or resource-constrained places. Such advances have the potential to transform supply chains and increase access to important biomolecules.

On March 2026, New England Biolabs (NEB) has announced the availability of the EnClose Cell-free dbDNA Synthesis Kit, which was created in partnership with Touchlight. This unique kit allows for the benchtop enzymatic synthesis of Touchlight’s proprietary doggybone DNA (dbDNA), a linear, covalently closed, double-stranded DNA that provides researchers with a fast, cell-free alternative to standard plasmid DNA for the development of diverse nucleic acid treatments. The technology is linearly scalable from research to production, making it an ideal template for viral vector production, including adeno-associated virus (AAV) and lentiviral (LV) vectors, non-viral gene therapy, and a variety of nucleic acid therapeutics such as mRNA therapeutics and gene editing.

Recent Trends:

Emerging trends include automation and benchtop DNA synthesis platforms, AI and bioinformatics integration, microfluidics and chip-based DNA synthesis, DNA data storage technologies, and point-of-care and decentralized DNA synthesis.

DNA data storage technologies are emerging as a major trend because the world is generating massive amounts of digital data through artificial intelligence, cloud computing, IoT devices, social media, and genomics research. Unlike conventional storage devices that degrade within years, DNA can preserve data for hundreds or even thousands of years under proper conditions. Additionally, DNA storage consumes significantly less energy because it does not require constant power or cooling systems, making it attractive for sustainable data management and archival storage.

Advancements in EDS technologies are further accelerating this trend by enabling faster, more accurate, and environmentally friendly DNA writing processes. Improvements in sequencing technologies, automation, and bioinformatics are also reducing operational costs and improving scalability. As a result, DNA data storage is gaining attention as a future solution for large-scale, long-term digital data preservation.

Restraints & Challenges:

Enzymatic DNA synthesis has difficulties in fidelity for long constructs, making it less suitable for complicated genetic designs. Furthermore, combining this technology with existing high-throughput screening equipment is a difficulty. Furthermore, enzymes such as TdT (terminal deoxynucleotidyl transferase) are prone to unintentional additions, resulting in contaminants. Secondary structures in DNA can potentially disrupt enzyme action, particularly when working with longer sequences or complicated patterns.

Aqueous environments can cause newly synthesized single-stranded DNA to fold into complex secondary structures (such as hairpins). These structures can block the enzyme from accessing the 3′-terminus, stalling synthesis and reducing overall yields. Achieving high reproducibility and throughput for long strands in automated systems remains challenging compared to standard phosphoramidite chemistry, requiring further enzyme engineering and process optimization.

Product and Services Segment Insights and Analysis:

Based on the product and services, enzymatic DNA synthesis market is segmented into instruments & platforms, reagents & consumables, software & bioinformatics, and services.

Instruments & platforms segment contributed the largest market share in 2025. As demand for synthetic biology, gene therapy, precision medicine, and genomics research increases, laboratories and biotechnology companies are increasingly adopting advanced DNA synthesis instruments to improve workflow efficiency and reduce turnaround time. Modern enzymatic DNA synthesis platforms, including benchtop DNA printers, automated synthesis systems, and microfluidic platforms, allow researchers to produce DNA on demand within their own facilities. Automated platforms also improve synthesis accuracy, reduce manual errors, and support high-throughput DNA production, which is essential for applications such as CRISPR research, vaccine development, and synthetic biology.

On May 2026, 4basebio PLC has announced the commercial introduction of its high-capacity single-stranded DNA (ssDNA) product line, which will speed the development of safer, more precise genetic therapeutics by allowing for targeted gene editing, improved cell engineering, and novel nucleic acid-based medications. The platform, which is based on a proprietary enzymatic manufacturing process, provides biopharma with high-purity, long-form ends protected ssDNA templates. It is designed to overcome critical manufacturing and performance bottlenecks associated with traditional chemical synthesis in CRISPR-based gene editing, allowing for large-scale, clinically viable therapeutics.

Technology Segment Insights and Analysis:

Based on the technology, enzymatic DNA synthesis market is segmented into template-independent enzymatic synthesis, chip-based enzymatic synthesis, CRISPR-assisted synthesis platforms, and hybrid synthesis platforms.

Template-independent enzymatic synthesis segment contributed the largest market share in 2025. It offers major advantages over traditional chemical DNA synthesis methods in terms of accuracy, scalability, sustainability, and long-fragment DNA production. This technology uses enzymes such as Terminal deoxynucleotidyl Transferase (TdT) to add nucleotides sequentially without requiring a DNA template, enabling highly flexible and controlled DNA synthesis processes.

The technology is also gaining traction because it operates under mild aqueous conditions and eliminates the use of hazardous chemicals commonly associated with chemical synthesis. This aligns with the biotechnology industry’s growing focus on sustainable and environmentally friendly manufacturing practices. In addition, it supports automation and high-throughput workflows through integration with benchtop DNA printers, and AI-driven synthesis platforms.

On May 2025, Ribbon Bio GmbH, a DNA synthesis firm, has announced the release of MiroSynth DNA, its first commercial product aimed at meeting the growing need for complex and highly accurate synthetic DNA molecules. MiroSynth DNA is based on Ribbon’s proprietary algorithm-driven technology and precision enzymatic assembly method, providing superior accuracy and performance for biopharma, life sciences, and academic research.

Application Segment Insights and Analysis:

Based on the application, enzymatic DNA synthesis market is segmented into synthetic biology, genetic engineering, vaccine, cell and gene therapy, and drug discovery & development.

Synthetic biology segment contributed the fastest growth rate in 2025. Enzymatic DNA synthesis (EDS) builds DNA sequences in moderate, aqueous circumstances using designed enzymes, in contrast to standard phosphoramidite chemistry, which depends on severe chemical reactions. This biomimetic strategy makes use of the machinery found in nature, namely modified polymerases that are capable of precisely adding nucleotides in a regulated, stepwise fashion. The end product is a synthesis technique that preserves the accuracy required for contemporary molecular biology applications while avoiding the hazardous circumstances and hazardous solvents of chemical synthesis.

Synthetic cells in biomedicine can deliver therapeutics to disease areas. These systems can release medications in response to precise molecular cues, increasing targeting accuracy and lowering adverse effects. Furthermore, synthetic cells with oscillatory circuits have the potential for time-sensitive medical applications such as chronotherapy, in which medication release timing is crucial for efficacy maximization. As a foundational technique, enzymatic DNA synthesis continues to push the boundaries of synthetic cell growth, allowing for more complex and multifunctional designs.

On October 2025, Ansa Biotechnologies, a synthetic DNA maker based in California, has raised USD 45.2 million in Series B funding. Cerberus Ventures led the round, with participation from previous investors Blue Water Life Science Advisors and Altitude Life Science Ventures. Ansa intends to use some of the funds to expand its only facility, Gammack, located in Emeryville, California. Ansa plans to use the Series B to enhance its R&D skills and demonstrate the versatility of its DNA technology for various applications.

Geographical Outlook:

Enzymatic DNA Synthesis market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America Enzymatic DNA Synthesis Market:

North America is registered to have highest market share in enzymatic DNA synthesis market in 2025, due to its strong biotechnology ecosystem, advanced genomics infrastructure, high research and development spending, and presence of leading synthetic biology and gene therapy companies. The region is a major hub for innovation in DNA synthesis technologies, particularly in applications such as synthetic biology, precision medicine, vaccine development, and gene editing. Academic institutions, pharmaceutical companies, and biotechnology firms across North America are actively investing in automated and high-throughput enzymatic DNA synthesis systems to accelerate therapeutic development and reduce dependence on conventional chemical synthesis methods.

On May 2024, Molecular Assemblies, Inc., has announced the establishment of its Partnering Program, which will license the company’s Fully Enzymatic Synthesis (FES) technology for onsite synthesis. FES technology accelerates the manufacture of lengthy, clean, and precise DNA, enabling a new generation of quickly emerging medicines and diagnostics. Under the cooperation, a few select members will obtain MAIs’ automated synthesis platform, all proprietary reagents and enzymes, and any expansions or improvements to its FES platform, as well as the appropriate licenses to conduct FES for research purposes in their facilities.

Asia Pacific Enzymatic DNA Synthesis Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period. Growing support for biological research and drug discovery is increasing the demand for a consistent supply of synthetic nucleotides for various research applications. The presence of numerous ongoing research projects across research institutions in the region, along with the emergence of new market participants, is contributing significantly to market expansion. Additionally, rising investments and continuous development of innovative technologies by leading industry players are further driving the growth of the Asia-Pacific enzymatic DNA synthesis market.

On May 2025, DNA Script, a DNA synthesis pioneer that provides scientists with rapid, on-demand access to high-quality DNA, announced distribution agreements with Gencell, Bio-Medical Science Co. (BMS), and Biostream. These agreements expand global access to the Company’s SYNTAX platform for decentralized, in-house, and on-demand oligonucleotide production. According to the agreements, Gencell will market SYNTAX throughout Latin America, Bio-Medical Science will cover South Korea, and Biostream will help customers in Japan.

Competition Analysis:

Enzymatic DNA synthesis market is characterized by a consolidated structure, with few players competing across various segments and regions. List of major players included in enzymatic DNA synthesis market report are:

• DNA Script SAS
• Ansa Biotechnologies
• Twist Bioscience
• TriLink BioTechnologies
• Kura Biotech
• Touchlight
• Telesis Bio Inc.
• Thermo Fisher Scientific Inc.
• Camena Biosciences
• Ribbon Bio GmbH
• Applied DNA Sciences, Inc.

Strategic Developments in Enzymatic DNA Synthesis Market:

• In April 2026, NunaBio, a Newcastle University spinout, has secured GBP 6.5 million in finance to expand its patented DNA platform. The cash will allow NunaBio to continue its research into a novel approach to DNA production. This will accelerate the development of vaccinations, gene treatments, diagnostics, and other life-changing technologies. Northstar Ventures spearheaded the investment, using funding from the North East Innovation Fund, the North East Spinout Inspire Fund, and the Northstar EIS Growth Fund.
• In October 2025, Telesis Bio Inc., a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery through fast and flexible on-site automated foundries, has announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio’s revolutionary Gibson SOLA platform at its R&D core facilities. This will enable Regeneron to implement automated, high-throughput, on-demand gene synthesis in their own laboratories. The Gibson SOLA platform has been shown to allow for completely enzymatic, overnight, on-site synthesis of exceptionally high-fidelity DNA and mRNA, lowering design-to-build times from weeks to hours.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2023 to 2024, with 2025 serving as the base year for market size calculations. The forecast period extends from 2026 to 2033.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of Enzymatic DNA Synthesis Market Report:

Enzymatic DNA Synthesis market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2023-2024 and revenue forecasts for 2026-2033 across the following segments:

• Product and Services Outlook (Revenue, USD Million; 2023-2033)
  • Instruments & Platforms
  • Reagents & Consumables
  • Software & Bioinformatics
  • Services
    • Oligonucleotide Synthesis Services
    • Gene Synthesis Services
    • DNA Library Synthesis
    • Cloning & Assembly Services

• Technology Outlook (Revenue, USD Million; 2023-2033)
  • Template-Independent Enzymatic Synthesis
  • Chip-Based Enzymatic SynthesisCRISPR-Assisted Synthesis Platforms
  • Hybrid Synthesis Platforms

• Synthesis Length Outlook (Revenue, USD Million; 2023-2033)
  • Short Oligonucleotide
  • Medium-Length
  • Long DNA Contructs

• Application Outlook (Revenue, USD Million; 2023-2033)
  • Synthetic Biology
  • Genetic Engineering
  • Vaccine
  • Cell and Gene Therapy
  • Drug Discovery & Development

• End-Use Outlook (Revenue, USD Million; 2023-2033)
  • Pharmaceutical & Biotechnology Companies
  • Research Institutes
  • Hospitals & Diagnostic Laboratories
  • Contract Research Organizations (CRO)

• Regional Outlook (Revenue, USD Million; 2023-2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about Enzymatic DNA Synthesis Market report